Am I Eligible for Semaglutide in India? The Complete Clinical Checklist (2026)

With generic semaglutide now available in India from as little as ₹1,290 per month — compared to ₹16,400 just months ago — millions of Indians are asking a single question: am I eligible to take it?

It is a reasonable question. The clinical evidence is compelling. The STEP 1 trial, published in the New England Journal of Medicine, showed a mean weight loss of 14.9% over 68 weeks.^[1] The SELECT trial demonstrated a 20% reduction in heart attacks, strokes, and cardiovascular death in patients with obesity and established cardiovascular disease.^[2] In a country where 101.3 million adults live with diabetes and 254 million carry generalised obesity,^[3] the arrival of affordable GLP-1 therapy represents a meaningful shift in access.

But semaglutide is not for everyone. It is a prescription medication with real contraindications, a dose-escalation protocol that requires medical supervision, and side effects that need to be managed appropriately. Eligibility is not simply a matter of wanting to lose weight.

This checklist outlines the key clinical factors that determine eligibility for semaglutide in India — using Indian thresholds, not the Western criteria that most international resources apply.

Why Indian eligibility criteria differ from Western guidelines

Before working through the checklist, this distinction is essential and almost universally misunderstood by patients researching online.

The US FDA approved semaglutide at a BMI threshold of 27 or higher (with comorbidities) or 30 or higher (without). These thresholds were derived primarily from the SELECT trial, which enrolled a population that was 84% white, with South Asians representing barely 8% of participants.^[2]

The data on Indian bodies tells a different story. South Asians develop metabolic disease at significantly lower BMI values than Western populations. A nationally representative ICMR study found that 43.3% of Indian adults are metabolically obese despite having a BMI below 25.^[4] Indians accumulate visceral fat — the metabolically active fat that drives insulin resistance, cardiovascular disease, and diabetes — at body weights that would be classified as normal by Western standards. This is the well-documented "thin-fat Indian phenotype."^[5]

The WHO Asia Pacific guidelines, the Endocrine Society of India (ESI) clinical practice guidelines,^[6] and the India Obesity Consensus published in the Journal of the Association of Physicians of India (2023)^[7] all recommend lower BMI thresholds for Indian patients:

Overweight for Indians: BMI ≥23 kg/m²
Obese for Indians: BMI ≥25 kg/m²

This is the framework GLP-1 Check's triage tool is built on — and it is why an Indian patient with BMI 26 and type 2 diabetes may be a strong candidate for semaglutide, even though a Western eligibility calculator would indicate otherwise.

The eligibility checklist — step by step

Step 1: Calculate BMI and waist-to-height ratio

BMI alone is an imperfect measure for Indians, but it remains the clinical starting point. It is calculated as: weight (kg) ÷ height (m)².

As an example, a 35-year-old Indian woman who is 160 cm tall and weighs 72 kg has a BMI of 28.1.

Indian BMI thresholds for semaglutide consideration:

BMI range	Classification (Indian)	Semaglutide consideration
Below 23	Normal weight	Generally not eligible (unless T2D with specific indications)
23 – 24.9	Overweight	Possible with significant comorbidities — discuss with your doctor
25 – 27.4	Obese (Indian definition)	Eligible with at least one comorbidity
27.5 and above	Obese (DCGI approval threshold)	Eligible — comorbidity not required but significantly strengthens the case

Waist circumference matters too. For Indians, abdominal obesity is defined as waist ≥90 cm in men and ≥80 cm in women, per WHO Asia Pacific guidelines.^[8] Patients with BMI in the 23–25 range whose waist measurement exceeds these values may carry significantly more visceral fat than their weight alone suggests. Waist circumference should be measured at the midpoint between the lowest rib and the top of the hip bone.

A waist-to-height ratio above 0.5 is another clinically useful marker. This is calculated by dividing waist circumference (cm) by height (cm). A person who is 165 cm tall with an 85 cm waist has a ratio of 0.52 — in the elevated risk range.^[4]

Step 2: Assess comorbidities

Comorbidities are the conditions that most strongly support semaglutide eligibility. The presence of even one of the following significantly strengthens the clinical case for treatment:

Strong indications (each independently supports eligibility):

Type 2 diabetes mellitus — The strongest single indication. Semaglutide is recommended as first-line pharmacotherapy for T2D with obesity per ESI India guidelines.^[6] HbA1c ≥6.5% or fasting glucose ≥126 mg/dL confirms the diagnosis.
Prediabetes — Defined as HbA1c between 5.7% and 6.4%, or fasting glucose between 100–125 mg/dL. The STEP 5 trial showed semaglutide restored normal blood sugar in 84–89% of prediabetic patients over 104 weeks.^[9] With an estimated 136 million Indians living with prediabetes,^[3] this remains a largely underrecognised indication.
Established cardiovascular disease — A history of heart attack, stroke, or peripheral arterial disease. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in patients with obesity and CVD.^[2] This is now considered a standalone indication regardless of weight-loss goals.
PCOS (Polycystic Ovary Syndrome) — Affects approximately 1 in 5 Indian women. Insulin resistance is the shared mechanistic pathway between PCOS and obesity, and GLP-1 therapy directly targets this pathway. The India Obesity Consensus (JAPI, 2023) specifically supports GLP-1 use in PCOS with insulin resistance.^[7]
Hypertension — Controlled or uncontrolled high blood pressure (BP ≥130/80 mmHg). The STEP trials demonstrated meaningful blood pressure reduction as a secondary endpoint.^[1]
Non-alcoholic fatty liver disease (NAFLD/MASH) — Increasingly prevalent in Indian patients, even those at normal BMI. Semaglutide demonstrated MASH resolution in 59% of patients in a Phase 2 trial.
Obstructive sleep apnoea — Weight-related sleep apnoea is both a supporting indication and a condition that typically improves with GLP-1-mediated weight loss.
Dyslipidaemia — Elevated triglycerides (≥150 mg/dL) or low HDL cholesterol are components of metabolic syndrome and strengthen the eligibility case.^[1]

Step 3: Check for absolute contraindications

The following conditions are absolute contraindications. If any apply, semaglutide is not appropriate regardless of BMI or comorbidity profile:

Personal or family history of medullary thyroid carcinoma (MTC) — Semaglutide carries a boxed warning for thyroid C-cell tumours. A personal or family history of MTC is an absolute contraindication.^[6]
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — An absolute contraindication per ESI India guidelines.^[6]
History of pancreatitis — Active pancreatitis or a confirmed history of chronic pancreatitis contraindicates semaglutide use. Acute pancreatitis has been reported as a rare adverse event in clinical trials.
Pregnancy or breastfeeding — Semaglutide is not approved for use during pregnancy. Women planning pregnancy should discuss stopping semaglutide at least two months before attempting conception, per WHO GLP-1 guidelines.^[10]

Conditions requiring caution and close monitoring (not absolute contraindications, but requiring specialist discussion):

Gallbladder disease — semaglutide increases gallstone risk slightly
Severe kidney disease (eGFR below 15)
History of eating disorders
Age above 75 — no absolute contraindication, but clinical caution is warranted regarding sarcopenia risk

Step 4: Consider prior lifestyle intervention

Semaglutide is approved as an adjunct to diet and exercise — not a standalone treatment. Patients who have made multiple sustained attempts at weight loss through dietary and activity changes without maintaining results are strong candidates for pharmacological support. The India Obesity Consensus (JAPI, 2023) explicitly cites failed prior weight-loss attempts as a key factor supporting pharmacotherapy initiation.^[7]

This does not mean a patient must have failed for years before being eligible. It means semaglutide is most appropriate — and most effective — when combined with genuine dietary and activity changes, not taken as a substitute for them.

Step 5: Age eligibility

Semaglutide for obesity is approved in India for adults aged 18 and above. There is no upper age hard limit, but patients above 75 require additional evaluation for sarcopenia risk (muscle loss) and renal function before initiating therapy.

The role of blood test results

Where recent lab values are available, they significantly sharpen the eligibility picture. The most clinically useful markers are:

HbA1c — The single most important glycaemic marker. ≥6.5% confirms T2D. 5.7–6.4% confirms prediabetes. Both are strong GLP-1 indications.^[6]
Fasting blood glucose — ≥126 mg/dL confirms T2D. 100–125 mg/dL confirms prediabetes.
Triglycerides — ≥150 mg/dL indicates metabolic risk and metabolic syndrome.
HDL cholesterol — Below 40 mg/dL in men and 50 mg/dL in women indicates metabolic syndrome.
Blood pressure — Stage 1 hypertension (≥130/80 mmHg) supports eligibility.

All six values are not required. Even one confirmed abnormal marker meaningfully strengthens the clinical case for GLP-1 therapy.

A case example: the patient commonly missed

Consider the following clinical profile — a 42-year-old woman with a BMI of 24.8. By Western standards, she would be classified as normal weight and told she does not qualify for weight-loss medication. Her full clinical picture tells a different story:

Waist circumference 88 cm (above the Indian cut-off of 80 cm for women)^[8]
Fasting glucose 112 mg/dL (prediabetes range)
HbA1c 6.1% (prediabetes confirmed by two markers)
Triglycerides 178 mg/dL (borderline elevated)
PCOS diagnosed at age 28
Three previous sustained attempts to lose weight through dietary intervention, all unsuccessful

By Indian clinical guidelines, this patient is a strong candidate for semaglutide. Her BMI exceeds the Indian overweight threshold of 23. Her abdominal obesity is confirmed by waist circumference. Her prediabetes is confirmed by two independent markers. Her PCOS shares the same insulin-resistance mechanism that GLP-1 therapy directly addresses.^[7]

A Western BMI calculator would have sent her away. Indian clinical guidelines support a conversation about treatment.

Who is clearly not a candidate

Eligibility information should work in both directions. Semaglutide is not appropriate for the following:

Those seeking cosmetic weight loss — Semaglutide is a treatment for metabolic disease, not a cosmetic slimming injection. Misuse at healthy body weights carries real risks including muscle loss, nausea, gallstones, and gastrointestinal harm.
Adults with BMI below 23 and no comorbidities — Below the Indian overweight threshold with no metabolic disease, the risk-benefit ratio does not support semaglutide use.
Pregnant or breastfeeding women — Absolute contraindication.
Anyone with a personal or family history of thyroid cancer (MTC) or MEN2 — Absolute contraindication regardless of obesity status.

How to use this checklist

Working through each step with accurate measurements and an honest medical history provides a useful starting point for a conversation with a qualified physician — an endocrinologist, diabetologist, or physician trained in obesity medicine — who can review the full clinical picture and make the final determination.

Semaglutide is a prescription drug in India. It requires physician assessment and ongoing monitoring. This checklist is not a substitute for that evaluation — it is a preparation tool designed to help patients arrive at that conversation informed, with the right questions and a clearer sense of whether pursuing treatment is worth exploring.

GLP-1 Check's free 5-minute clinical assessment applies these exact Indian thresholds to generate a Green, Amber, or Red readiness score — with the clinical evidence behind each decision fully disclosed.

Key data points

101.3 million Indians live with diabetes^[3]
254 million Indians carry generalised obesity^[3]
43.3% of Indians are metabolically obese at normal BMI^[4]
STEP 1 trial: 14.9% mean weight loss over 68 weeks^[1]
SELECT trial: 20% reduction in major cardiovascular events^[2]
STEP 5 trial: 84–89% of prediabetic patients restored to normal blood sugar over 104 weeks^[9]
Indian overweight threshold: BMI ≥23; Indian obesity threshold: BMI ≥25^[5]^[6]
Generic semaglutide in India: ₹1,290–4,500 per month as of March 2026

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. PubMed
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial). New England Journal of Medicine. 2023;389:2221–2232. PubMed
Anjana RM, et al. Metabolic Non-Communicable Disease Health Report of India — ICMR-INDIAB-17. Lancet Diabetes & Endocrinology. 2023;11(7):474–489. PubMed
ICMR-INDIAB-23: High Prevalence of Metabolic Obesity in India. Indian Journal of Medical Research. 2025. PMC
Defining and Diagnosing Obesity in India: A Call for Advocacy and Action. Journal of Internal Medicine. 2023. PMC
Endocrine Society of India (ESI). Clinical Practice Guidelines for the Evaluation and Management of Obesity in India. PMC
Consensus on Current Landscape and Treatment Trends of Obesity in India for Primary Care Physicians. Journal of the Association of Physicians of India. 2023. PubMed
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet. 2004;363(9403):157–163.
Husain M, et al. Semaglutide in Patients with Prediabetes — STEP 5 Trial. The Lancet. 2024. PubMed
World Health Organization. Guideline on the Use of GLP-1 Therapies for the Treatment of Obesity in Adults. December 2025. WHO

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified physician before starting any treatment. Semaglutide is a prescription drug in India and must only be taken under medical supervision.